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Introduction
Hepatitis B virus (HBV) remains a major global healthcare chal-
lenge, with over 400 million chronically infected worldwide 
(1). HBV is a DNA virus that infects hepatocytes and establishes 
a mini-chromosome (cccDNA) that acts as a template for HBV 
replication and antigenic production (2). Nucleos(t)ide-analogue 
(NUC) therapy suppresses viral replication, but does not suc-
cessfully eliminate cccDNA, thus leading to HBV rebound and 
development of hepatic flares upon treatment withdrawal (3). 
Life-long NUC therapy, which is therefore required in the major-
ity, represents a financial burden for patients and national health 
systems. Concerns of potential drug toxicity (4) and the selection 
of mutants that could possibly escape prophylactic vaccination are 
also important considerations (5). Thus, a major unmet need in 
the management of chronic HBV patients is the definition of bio-
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IU/ml (7) in HBV e-antigen–negative (HBeAg-negative) patients is 
recommended by some as a safe stopping point; however, such 
values are observed in a minority of NUC-treated patients. The 
recent FINITE study of stopping NUC therapy in HBeAg patients 
markers that can predict the safe discontinuation of NUC therapy. 
There is no consensus on current treatment guidelines on the opti-
mal time to consider stopping NUC therapy (6). Seroconversion of 
the surface antigen of HBV (HBsAg) or HBsAg to values below 100 
Figure 1. CONSORT-style flow diagram. Enrollment, follow-up, and analysis before and after stopping NUC therapy for the UK (cohort 1, left) and Asian 
(cohort 2, right) chronic HBV patient cohorts. For more details on the enrolled patients, refer to Tables 1 and 2. HCC, hepatocellular carcinoma.
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we characterized the functional profile of both antigen-specific T 
cells and global non–antigen-specific immunity in chronic HBV 
patients during NUC therapy. Traditional immunological assays 
(ELISPOT, flow cytometry) (13) were utilized to detect the fre-
quency, functionality, and fine specificity of HBV-specific T cells 
in conjunction with methods of analysis of the global non–anti-
gen-specific immune populations (Cytometry by Time-of-Flight 
[CyTOF], NanoString). CyTOF, a mass cytometry technology (14), 
was used to define the frequency and phenotype of global T, NK, 
and B cell populations, while NanoString technology was utilized 
to analyze the transcriptional profiles of immune gene expression 
in purified CD4+ and CD8+ T cell subsets.
Two distinct cohorts of 19 and 27 HBeAg-negative chronic 
HBV patients who withdrew from long-term antiviral therapy were 
studied longitudinally during and after stopping NUC treatment. 
Results from the 2 cohorts demonstrate that patients who dis-
continue NUC therapy without subsequently developing hepatic 
flares are characterized by increased frequencies of HBV-specific 
T cells, which can be expanded preferentially from the PD-1+ T cell 
reports that 13 out of 21 patients were able to remain off therapy 
for nearly 3 years, yet no criteria that distinguishes which patients 
can safely discontinue therapy is identified (8). Since antiviral 
immunity plays a critical role in the suppression and control of 
HBV infection, we sought to identify immunological biomarkers 
to predict whether NUC therapy can be safely discontinued.
During the natural history of chronic HBV, the quantity and 
function of HBV-specific T cells are shown to correlate with HBV 
control (9). Moreover, components of innate immunity, such as NK 
cells, can modulate HBV control or HBV-specific T cell quantity 
(10). Recent studies show that NK cells with a less “inflammato-
ry” phenotype (expressing lower frequencies of CD38, Ki-67, and 
TRAIL) were associated with HBsAg seroconversion and may rep-
resent a potential marker for safe NUC suspension (11). Further-
more, it was recently reported that a transcriptional T cell signature 
that is linked to CD8+ T cell exhaustion and CD4+ T cell costimula-
tion can predict the outcome of chronic viral infection (12).
Thus, in order to define possible immune markers associat-
ed with HBV control or viral relapse upon NUC discontinuation, 
Figure 2. Characteristics of the patient cohort. (A) Schematic depicting the study 
design. Patients were enrolled for the study and maintained on NUC therapy for 1 
year (48 weeks), after which therapy was discontinued. Weeks are calculated from 
therapy discontinuation (week 0). (B) Upon stopping therapy, patients were classified 
as nonflare (2 representative patients [n = 13], left top and bottom panels) or flare (2 
representative patients [n = 6], right top and bottom panels) based on ALT and HBV 
DNA values observed in the 6 months (24 weeks) following therapy discontinuation. 
Nonflare and flare, patients with ALT values below or above 2× ULN (80 IU/ml), 
respectively. (C) Serum HBsAg values observed in all patients, subdivided as flare 
and nonflare upon therapy withdrawal. HBsAg values are measured longitudinally at 
weeks 0, 12, and 48 from NUC withdrawal. HBsAg values are expressed as IU/ml.
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were 100 times greater compared with those that did not flare (n = 
13/19 = 68.4%) (Figure 2B and Table 1). HBsAg values during NUC 
therapy and HBV DNA levels before the start of therapy did not 
differ in patients from the 2 groups (Figure 2C and Table 1).
Increased frequencies of HBV-specific T cells in patients with HBV 
control. During the natural history of HBV, viral control is propor-
tionally associated with greater frequencies of HBV-specific T 
cells (15), which are also critical for viral control in a nonhuman 
primate model (16). We thus asked whether the HBV-specific T 
cell response differs between those who develop viral relapse and 
those who do not upon NUC withdrawal. In line with previous stud-
ies reporting the inability to detect HBV-specific T cells ex vivo in 
chronic HBV patients (13, 15, 17), we were unable to detect HBV-spe-
cific T cells in the peripheral blood of HLA-A*0201+ patients by 
using HBV-peptide HLA-A*0201 pentamers (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/JCI92812DS1). To increase the sensitiv-
ity of detection of HBV-specific T cells and comprehensively test 
the presence of T cells specific for the whole HBV proteome, we 
expanded patient peripheral blood mononuclear cells (PBMCs) for 
10 days with a panel of overlapping 15-mer peptides spanning the 
HBV proteome (x, core, envelope, and polymerase), as described 
previously (13). T cell recognition of the peptides pooled according 
to the single proteins was subsequently tested by IFN-γ ELISPOT. 
Patient PBMCs were tested at 3 time points prior to and after stop-
ping therapy (weeks –36, –12, +28, where week 0 represents the 
time of therapy discontinuation). We show that the frequencies 
of in vitro–expanded HBV-specific T cells during NUC therapy 
were significantly higher in patients that did not flare upon therapy 
fraction. Thus, this study proposes a candidate biomarker for safe 
therapy withdrawal and, in addition, suggests that during human 
chronic viral infection, virus-specific T cells expressing inhibitory 
markers may escape deletion and retain a partial functional capac-
ity that allows them to mediate protective antiviral immunity.
Results
Definition of the chronic HBV patient cohort. Twenty-nine 
HBeAg-negative chronic HBV patients on long-term antiviral ther-
apy with a combination of tenofovir disoproxil fumarate (TDF) 
and lamivudine (LAM) (virally suppressed with normal levels of 
transaminases for at least 18 months) were enrolled (Figure 1, 
cohort 1). At the start of the study, for safety concerns, one drug 
was discontinued first (TDF), after which patients received anti-
viral monotherapy with LAM for 48 weeks before complete NUC 
withdrawal. Patients were routinely monitored at 4-week inter-
vals, and peripheral blood was longitudinally sampled during the 
LAM monotherapy and following complete therapy discontinua-
tion for up to 2 years (Figure 2A). During the 48 weeks of mono-
therapy, 6 of the enrolled patients experienced an increase in HBV 
DNA and were excluded and another 2 patients elected to remain 
on LAM monotherapy. Following complete NUC discontinua-
tion, patients differentiated into 2 groups based on the presence 
or absence of hepatic flares during a 6-month (24 week) period 
subsequent to treatment withdrawal. Nonflare or flare patients 
were defined based on serum alanine aminotransferase (ALT) val-
ues below (≤80 IU/ml) or above (>80 IU/ml) 2× the upper limit of 
normal (ULN), respectively. During viral rebound, patients with 
hepatic flares (n = 6/19 = 31.6%) displayed levels of HBV DNA that 
Table 1. Details of the therapy discontinuation cohort of chronic HBV patients (cohort 1)
Patient details Before NUC At stop NUC After NUC
ID Sex Age at  
enrollment (yr)
HBV 
genotype
ALT 
(IU/l)
HBV DNA 
(103 IU/ml)
HBsAg  
(IU/ml)
Peak ALT 
(IU/l) (wk)
Max HBV DNA 
(103 IU/ml)
log2 fold-change 
HBV DNA after NUC
Back on 
NUC (wk)
Nonflare
NF 1 M 43 B 539 776.25 965 28 (16) 1.05 –9.54 No (>252)
NF 2 M 60 D NA NA 0.4 13 (0) 0.02 NA No (>255)
NF 3 M 49 C 79 213.80 585 49 (8) 3.45 –5.95 No (>296)
NF 4 F 32 D 113 758.58 6964 80 (24) 29.35 –4.69 Yes (82)
NF 5 F 46 D 54 4073.80 3844 50 (16) 5.44 –9.55 Yes (120)
NF 6 M 55 D 47 40738.03 5795 80 (48) 64.56 –9.30 Yes (48)
NF 7 F 65 D 52 1023.29 5826 73 (16) 654.08 –0.65 Yes (16)
NF 8 M 52 D 87 3235.94 ND 79 (56) 0.17 –14.20 Yes (60)
NF 9 M 38 D 30 1.23 1573 66 (8) 12.37 3.33 No (>220)
NF 10 M 50 B 28 165.96 481 67 (10) 172.10 0.05 Yes (46)
NF 11 F 44 A 46 21.38 4152 30 (8) 255.67 3.58 Yes (84)
NF 12 F 33 E 16 17.78 22318 26 (16) 150.37 3.08 Yes (32)
NF 13 M 55 B 43 630.96 874 52 (8) 859.83 0.45 Yes (100)
Flare
F 1 M 47 D 131 14.79 4576 209 (8) 53 × 103 11.81 Yes (8)
F 2 M 40 D 133 4677.35 13046 154 (24) 22.4 × 103 2.26 Yes (24)
F 3 M 62 C 60 3890.45 672 332 (12) 122.2 × 103 4.97 Yes (12)
F 4 M 50 B 58 407.38 3389 197 (12) 337.6 × 103 9.69 Yes (12)
F 5 M 44 D 49 1.02 2293 528 (12) 37.3 × 103 15.15 Yes (12)
F 6 M 43 D NA NA 1018 565 (16) 1200 × 103 NA Yes (8)
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Figure 3. Increased frequencies of circulating HBV core and polymerase-specific T cells in chronic HBV patients undergoing NUC therapy that do not flare 
upon therapy discontinuation. HBV-specific T cells were assessed after a 10-day expansion of patient PBMCs with a panel of overlapping 15-mer peptides 
spanning the HBV proteome, followed by IFN-γ ELISPOT in the presence of peptides pooled according to the single proteins (x, core, env, and pol). Results 
are expressed as spot-forming cells (SFC) relative to 105 PBMCs. (A) Total HBV-specific T cell responses during NUC therapy (n = 17). (B) Deconvolution of the 
HBV-specific T cell response from A into the single HBV proteins. T cell responses directed against core (C) or polymerase (D) are shown longitudinally at 
week –36 (±4 weeks) and –12 (±12 weeks) of NUC therapy and 28 (±8 weeks) weeks after therapy withdrawal. Each symbol represents a single patient; black 
and white symbols represent flare and nonflare patients, respectively. (E and F) Intracellular cytokine staining for the detection of IFN-γ and TNF-α produc-
tion by in vitro–expanded CD4+ and CD8+ T cells stimulated in the absence or presence of core and polymerase overlapping peptides or with PMA/ionomycin. 
Shown are plots from representative nonflare (left panel) and flare (right panel) patients (E). IFN-γ release assessed as in E is summarized for 4 patients 
from the nonflare group (F). The presence or absence of T cells targeting core (G) or polymerase (H) is shown for patients with or without flares in the 12 or 24 
weeks immediately after therapy withdrawal. NF, nonflare; F, flare. Statistics were calculated using the nonparametric, 2-tailed Mann-Whitney U test.
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withdrawal compared with those that flared (Figure 3A). Decon-
volution of the HBV-specific T cell repertoire revealed that, while 
responses against x and envelope were present at low frequencies 
in both patient groups, those targeting core and polymerase could 
be detected at significantly higher frequencies (Figure 3B) and lon-
gitudinally at different time points (Figure 3, C and D, and Table 1) 
in patients for whom NUC therapy could be safely removed. Fur-
ther analysis by intracellular cytokine staining demonstrated that 
HBV-specific T cells were mostly contained within the CD8+ T cell 
subset, with polymerase-specific T cells being present at higher 
frequencies compared with those specific for core (Figure 3, E and 
F, and Supplemental Figure 1B). In line with previous studies (18), 
the magnitude of the HBV-specific T cell response during hepatic 
flares appeared to be lower, or at least not superior, to that detected 
in patients that did not flare, suggesting that hepatic flares may not 
be driven by HBV-specific T cells. Thus, this comprehensive anal-
ysis of HBV-specific T cells shows that, during NUC therapy, the 
detection of core and polymerase-specific T cells that possess in 
vitro proliferative ability can predict whether patients may safely 
withdraw from NUC therapy (Figure 3, G and H).
Characterization of immune populations and transcriptional 
profiles associated with HBV control. We next investigated ex vivo 
whether non–HBV-specific components of the human immune 
system could be associated with HBV control after NUC therapy 
discontinuation. Recent studies have suggested that the frequen-
cy of NK cell populations may represent a potential marker for 
Figure 4. High-dimensional analyses by CyTOF of immune 
populations present in the peripheral blood of patients 
with and without evidence of flares upon therapy discon-
tinuation. PBMCs from patients with and without flares 
upon therapy discontinuation were briefly stimulated with 
PMA/ionomycin, stained with a panel of 40 antibodies, 
and analyzed by CyTOF. (A) Live cells were concatenated 
after downsampling and analyzed in parallel by t-SNE (left 
panels). Manually gated lymphocyte populations were 
then overlaid onto the total t-SNE map (right panels). (B) 
Pie charts showing the average relative frequency of the 
different lymphocyte populations within the 2 groups of 
patients. (C) Heatmaps showing the average frequency 
of expression of each immunological marker within the 
indicated lymphocyte populations of patients that flared or 
did not flare upon therapy discontinuation. The percent-
ages of positive expression are shown from low (black) to 
high (red). t-SNE plot shown in A shows 1 representative 
experiment. Data shown in B and C represent the average 
expression from 17 patients (n = 12 nonflare; n = 5 flare). 
All P values in C are greater than 0.05 as calculated by 
unpaired t test. See also Supplemental Figures 2 and 3.
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We next investigated by NanoString the transcriptional profile 
of 579 selected immune genes in CD4+ and CD8+ T cells sorted 
ex vivo from the peripheral blood of patients during NUC viral 
suppression. Patients that did not flare upon treatment with-
drawal displayed increased expression in CD8+ T cells of mRNAs 
encoding for the costimulatory proteins/inhibitory receptors (20) 
PD-1, TIM3, EGR2, KLRC1, and SLAMF1 (Figure 5, A and B). 
Furthermore, these patients exhibited decreased expression in 
CD4+ T cells of mRNAs encoding for immune markers, including 
CD45RA, BCL6, KLRG1, and CD39 (Figure 5A). A similar trend 
toward higher expression of PD-1 and TIM3 was observed by 
CyTOF in CD8+ T cells of patients that did not flare (Figure 5C). 
Similarly, at the protein level, CD45RA and KLRG1 displayed a 
trend toward decreased expression in CD4+ T cells of patients that 
did not flare (Figure 5C). The other markers that were differential-
ly expressed at the mRNA level in the 2 patient groups (Figure 5A) 
were not present in the CyTOF panel.
HBV-specific T cells are enriched in the PD-1+ T cell fraction. 
Among the differentially expressed genes, PD1 was upregulat-
ed with the highest significance (P = 0.009) in CD8+ T cells of 
patients that did not flare, suggesting that an upregulation of PD-1 
on T cells might be beneficial. Since recent studies have proposed 
an additional unappreciated role of PD-1 in the long-term sur-
vival of antigen-specific CD8+ T cells (21), we hypothesized that 
overexpression of PD-1 on T cells may allow HBV-specific T cells 
to escape deletion induced by chronic viral antigen stimulation. 
First, we noted that the levels of PD1 in total CD8+ T cells cor-
related with the frequencies of in vitro–expanded HBV-specific T 
cells (Figure 5D). We then tested directly to determine whether 
HBV-specific T cells were enriched in the PD-1+ T cell fraction. 
PD-1+ and PD-1– T cells were sorted ex vivo from patient PBMCs, 
cocultured with core and polymerase peptide–pulsed autologous 
antigen-presenting cells for 10 days, and tested for the presence 
of HBV-specific T cells by IFN-γ ELISPOT. Our results show that 
HBV core and polymerase-specific T cells were significantly 
enriched in the PD-1+ fraction compared with the PD-1– counter-
part in patients that did not flare upon therapy discontinuation (n 
= 6) and in a single patient from the flare group (only 2 patients 
from the flare group had detectable HBV-specific T cell respons-
es, but PBMCs during NUC therapy were available for only 1 of 
these 2 patients). Data are summarized for 7 patients in Figure 5E 
and are shown for each patient in Figure 5F.
Finally, analysis by CyTOF of PBMCs following brief polyclon-
al stimulation showed a tendency toward higher cytokine-produc-
ing capabilities of CD8+ PD-1+ T cells from patients that did not 
flare as compared with those that flared (Figure 5G). Taken togeth-
er, these data suggest that PD-1 expression on T cells may help to 
preserve a population of partially exhausted T cells specific for 
selected HBV antigens.
Validation in an independent patient cohort of chronic HBV 
patients undergoing single NUC therapy. This comprehensive 
immunological analysis was performed on an initial cohort of 19 
HBeAg-negative chronic HBV patients under long-term combi-
nation therapy (TDF/LAM) followed by 1 year of monotherapy 
(LAM; cohort 1). We next sought to validate our findings in a sec-
ond cohort of 27 HBeAg-negative chronic HBV patients, treated 
with a single NUC agent (entecavir [ETV], TDF, or telbivudine 
NUC suspension (11) and the identification of an immunological 
signature directly ex vivo would provide a more efficient and eas-
ily reproducible approach. Two distinct strategies were adopted. 
First, we utilized CyTOF to uncover the phenotypic and function-
al properties of peripheral immune cells. Second, mRNA expres-
sion analysis was performed to determine the genes involved in 
immune pathways in purified CD4+ and CD8+ T cell subsets by 
NanoString technology.
The expression of 40 parameters involved in T, B, and NK 
cell activation, differentiation, and exhaustion (Supplemen-
tal Table 1) was evaluated by CyTOF. To uncover the functional 
capacity of these cells, PBMCs were analyzed after a brief poly-
clonal stimulation followed by intracellular cytokine staining. An 
unsupervised analysis was performed by t-distributed stochastic 
neighbor embedding (t-SNE), an algorithm that maps cells with 
similar properties in close proximity, as previously described (19) 
(Figure 4A). To further visualize and characterize the populations 
of interest within the t-SNE maps, manual gating was performed 
(Figure 4, A and B; gating strategy shown in Supplemental Figure 
2). The expression of immune markers was investigated in the dis-
tinct populations (Figure 4C). These analyses demonstrate that, 
during NUC therapy, both patient groups displayed T, B, and NK 
cell populations of similar frequencies and phenotypic/functional 
properties (Figure 4 and Supplemental Figure 3). The only excep-
tion was represented by CD4+ T cells, since their frequencies were 
increased in patients that did not flare compared with those that 
flared (Supplemental Figure 3). However, there was a substantial 
overlap of the frequencies of CD4+ T cells among the 2 groups, and 
only half (5 out of 10) of the patients who did not flare upon ther-
apy discontinuation displayed CD4+ T cell frequencies that were 
higher compared with those observed in the patients that flared 
(Supplemental Figure 3).
Figure 5. Functional HBV-specific T cells are enriched in the PD-1+ T 
cell fraction. (A–C) mRNA expression of immune-regulatory genes was 
analyzed by NanoString in CD4+ and CD8+ T cells sorted from the peripheral 
blood of patients that flared (n = 7) or did not flare (n = 12) upon therapy 
discontinuation. The differentially expressed genes (>1.5-fold difference, 
P < 0.05) in CD4+ and CD8+ T cells from the 2 patient groups are shown by 
heatmap (A). PD1 expression by CD8+ T cells is also shown as normalized 
NanoString counts (B). Statistics are calculated by nonparametric, 2-tailed 
Mann-Whitney U test. The expression of immune-regulatory markers by 
CD4+ and CD8+ T cells from patients that did not flare or from those that 
flared upon therapy withdrawal was evaluated by CyTOF (C). Relative 
expression of each marker is plotted as z-score calculated for each experi-
ment (n = 12 nonflare; n = 5 flare; see Methods). All differences are not sta-
tistically significant after correcting for multiple comparisons with Holm-
Šidák or Šidák-Bonferroni method. (D) Pearson correlation of PD1 mRNA 
expression in total CD8+ T cells and frequencies of HBV-specific T cells. 
(E–F) PD-1+ and PD-1– T cells were sorted ex vivo from peripheral blood of 
patients (n = 7: n = 6 nonflare, n = 1 flare) and expanded in the presence of 
autologous antigen-presenting cells pulsed with HBV peptides. Expanded 
PD-1+ and PD-1– cells were tested for recognition of HBV peptides by IFN-γ. 
Data are summarized for 7 patients (E) and are shown for single patients 
(F). The ability of PD-1+ CD8+ T cells to produce cytokines and effector mol-
ecules following polyclonal stimulation was assessed by CyTOF in PBMCs 
of patients from the 2 groups (n = 12 nonflare; n = 5 flare) (G). Statistics 
were calculated using the nonparametric, 2-tailed Mann-Whitney U test 
except for in E, where the nonparametric Wilcoxon matched-pairs signed 
rank test was used. *P ≤ 0.05; **P ≤ 0.01.
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flare upon therapy withdrawal, confirming the findings from cohort 
1 in this second cohort (Figure 6A). Similarly to what was observed 
in cohort 1, deconvolution of the HBV-specific T cell repertoire 
revealed that, while responses against x and envelope were present 
at low frequencies in both patient groups, those targeting core and 
polymerase could be detected at higher frequencies in patients that 
did not flare (although this only reached statistical significance for 
core; Figure 6B). We next asked whether HBV-specific T cells were 
contained preferentially within the PD-1+ fraction, as was observed 
for cohort 1. PD-1+ and PD-1– T cells were sorted directly ex vivo from 
PBMCs of 6 patients on NUC therapy that did not flare upon thera-
py withdrawal, and cells were subsequently expanded with peptides 
spanning HBV core and polymerase proteins. After 10 days, PD-1+ 
and PD-1– cells were tested for HBV recognition by IFN-γ ELISPOT. 
Similarly in this cohort, HBV-specific T cells could be expanded 
preferentially from the PD-1+ fraction, as we had demonstrated for 
patients in cohort 1 (data summarized for n = 6 patients in Figure 6C 
and shown for the individual patients in Figure 6D).
However, mRNA gene expression by NanoString on purified 
CD4+ and CD8+ T cells did not confirm the differential expres-
sion of PD1 in CD8+ T cells in patients that did not flare compared 
with those that flared, and PD1 expression levels were low in both 
[LDT]; Figure 1, cohort 2). Of note, the 2 cohorts differed not only 
in the treatment regimes, but also in ethnicity and HBV-infecting 
genotype. Patients from cohort 1 were recruited in London (UK) 
and were heterogeneous in ethnicity and in HBV genotype of 
infection (A, B, C, D, or E). In contrast, patients from cohort 2 were 
recruited in Southeast Asia, were all of Han Chinese ethnicity, and 
were infected with HBV genotypes B or C, the predominant HBV 
genotypes present in this region (22) (Tables 1 and 2).
The clinical and virological profiles of the chronic HBV 
patients of cohort 2 are shown in Table 2. An identical grouping 
of flare versus nonflare patients based on similar parameters set 
for cohort 1 was adopted. Nonflare and flare patients were defined 
based on serum ALT values below (≤80 IU/ml) or above (>80 IU/
ml) 2× ULN, respectively, during an 8-month (35 week) period 
subsequent to treatment withdrawal.
Due to the limited number of cryopreserved PBMCs available 
for patients in cohort 2 while they were on NUC therapy, we focused 
our immunological analysis on the characterization of HBV-specific 
T cells after in vitro expansion with overlapping HBV peptides and 
on the analysis of mRNA gene expression on purified CD4+ and 
CD8+ T cells. A higher frequency of HBV-specific T cells was detect-
ed in those patients, while undergoing NUC therapy, that did not 
Table 2. Details of the patients from the validation cohort (cohort 2)
Patient information At stop NUC After stop NUC
ID Sex Age (yr) HBV genotype HBsAg (IU/ml) Peak ALT (IU/ml) Max DNA (103 IU/ml) Back on NUC (wk)
Nonflare
NF 1 M 70.5 B 222.5 38 1.13 No (61.6)
NF 2 M 53.4 B 427.5 34 0.5904 No (68)
NF 3 F 63.6 C 1228.5 22 1.7792 No (84.4)
NF 4 F 49.2 C 2124 40 1.63 No (96)
NF 5 M 47.7 B 122.5 61 0.609 No (103)
NF 6 F 58.7 B 569.5 24 0.0752 No (106.3)
NF 7 M 49.5 B 2560.5 38 0.066 No (109.7)
NF 8 M 28.1 B 1975 46  < 0.015 No (42.6)
NF 9 M 37.2 C 172 27 0.398 No (77)
NF 10 F 51.7 B 2330 37 4.596 No (146.6)
NF 11 F 41.5 B Positive 20  < 0.3 No (468)
NF 12 M 56.3 NA Positive 69 1599 Yes (56)
NF 13 M 48.7 B Positive 80 106 No (210)
NF 14 M 48.6 NA Positive 50 4.47 No (518)
NF 15 M 41.3 C Positive 78 0.1 Yes (71)
NF 16 F 33.6 NA Positive 42.0 1.6 No (472)
Flare
F 1 F 50.9 B 507.5 857 1259 Yes (9.9)
F 2 M 52.4 B 203.5 666 392 Yes (11.1)
F 3 M 66.0 C 1523.5 332 17 Yes (16.3)
F 4 M 52.0 B 1591 107 2324 Yes (17.0)
F 5 M 52.6 B 1497.5 184 129 Yes (21.7
F 6 F 56.9 B 420 1067 19900 Yes (22.4)
F 7 M 74.9 B 140.7 91 50 Yes (24.6)
F 8 M 36.8 B 1144 384 430 Yes (25.7)
F 9 M 33.8 C 3585 539 57 Yes (31.6)
F 10 M 51.8 C 9620 347 1595 Yes (35.1)
F 11 M 57.2 B Positive 315 73500 Yes (3.7)
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Pooled data from cohorts 1 and 2 showing the enrichment of 
HBV-specific T cells in the PD-1+ T cell fraction is shown in Figure 
6E. Pooled data from the 2 cohorts showing the increased frequen-
cies of HBV-specific T cells, in particular of those targeting core 
and polymerase, in patients that did not flare following therapy 
withdrawal is shown in Figure 6, F and G. Of note, our data identi-
fy a threshold of HBV core or polymerase-specific T cell frequen-
patient groups. Of the 579 immune genes that were analyzed by 
NanoString, 122 genes were differently expressed in CD4+ T cells 
and 137 in CD8+ T cells between the 2 groups of patients tested 
while undergoing NUC therapy (Supplemental Figure 4). Further-
more, the frequencies of CD4+ and CD8+ T cells were not different 
in patients that did and did not flare upon therapy discontinuation 
(Supplemental Figure 5).
Figure 6. Validation in an Asian patient cohort (cohort 2) of the increased frequencies of circulating HBV core and polymerase-specific T cells in chronic 
HBV patients undergoing NUC therapy that did not flare upon therapy discontinuation. HBV-specific T cells were assessed after 10-day expansion of 
patient PBMCs with a panel of overlapping 15-mer peptides spanning the HBV proteome, followed by IFN-γ ELISPOT in the presence of peptides pooled 
according to the single proteins (x, core, env, and pol). Results are expressed as spot-forming cells relative to 105 PBMCs. (A) Total HBV-specific T cell 
responses during NUC therapy (n = 26). (B) Deconvolution of the HBV-specific T cell response from A into single HBV proteins. (C) PD-1+ and PD-1– T cells 
were sorted ex vivo from peripheral blood of patients (n = 6) and expanded in the presence of autologous antigen-presenting cells pulsed with HBV core 
and polymerase peptides. Expanded PD-1+ and PD-1– cells were tested for recognition of HBV peptides by IFN-γ. Data are summarized for 6 patients (C) and 
are shown for the single patients (D). (E–G) Pooled data from cohorts 1 and 2 show IFN-γ production of ex vivo–sorted PD-1+ and PD-1– cells after in vitro 
expansion (n = 13; E), total HBV-specific T cell responses during therapy (n = 43; F), and the HBV-specific T cell response to single HBV proteins (G). The 
dotted line in G marks the threshold of HBV-specific T cell response associated with absence of hepatic flares upon therapy withdrawal. Circle and triangle 
symbols in F and G represent patients from cohort 1 and 2, respectively. Statistics were calculated using the nonparametric, 2-tailed Mann-Whitney U test 
except for in C and E, where the nonparametric Wilcoxon matched-pairs signed rank test was used. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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therefore favor their survival by limiting the excessive activation 
of these cells. Earlier studies showed that HBV-specific T cells 
could be detected in chronic HBV patients with lower levels of 
viremia and that these cells were mostly PD-1+ (26).
Of note, in both patient cohorts, HBV-specific T cells target 
exclusively core and polymerase, but not the envelope protein. 
This finding may suggest that HBV envelope–specific T cells 
have been deleted during the course of chronic infection due to 
high antigenic loads. In contrast, the presence of PD-1+ HBV core 
and polymerase-specific T cells selectively in patients with HBV 
control suggests that these cells may retain their antiviral capac-
ity and contribute to protection in vivo. However, only the direct 
analysis of these cells within the intrahepatic environment will 
provide direct evidence of their protective capacity and further 
our understanding of the mechanisms underlying HBV control 
in patients who do not relapse upon therapy withdrawal. It is evi-
dent that in these patients, HBV-specific T cells lack the ability to 
ultimately clear HBV infection and that, even after in vitro expan-
sion, their magnitude is lower than that of HBV-specific T cells 
present in patients with resolved acute HBV infection. Previous 
studies have shown that the function of PD-1+ HBV–specific T 
cells that are detectable in chronic HBV patients with lower lev-
els of viremia could be improved in vitro by blocking PD-1/PD-L1 
engagement (26). The implications of PD-1/PD-L1 therapy in 
vivo are, however, difficult to predict. Based on our findings, we 
speculate that a subgroup of HBV patients with detectable PD-1+ 
HBV–specific T cells (such as those that did not flare following 
therapy discontinuation) may benefit from PD1/PD-L1–blockage 
therapy, as this may lead to full functional recovery of partially 
exhausted HBV-specific T cells. Further studies are, however, 
needed to understand these processes.
The primary goal of this work was the definition of an immu-
nological marker for the safe discontinuation of NUC therapy. The 
association of PD-1+ HBV–specific T cells with HBV control in the 
absence of a hepatic flare is an important initial step forward toward 
achieving this goal. However, the methodology used for the analysis 
of antigen-specific T cells in vitro is lengthy, difficult to standard-
ize, and requires specialized technical skills that are not available in 
every laboratory. Thus, we sought to identify a biomarker directly 
ex vivo by utilizing high-throughput immunological methods such 
as CyTOF and NanoString. Unfortunately, these efforts did not lead 
to the identification of a biomarker that could be validated across 2 
independent cohorts. CyTOF analysis of PBMCs from patients of 
the first cohort revealed a correlation between increased frequen-
cies of CD4+ T cells and HBV control, but this was not confirmed 
in the second cohort. More strikingly, the association of higher PD1 
mRNA expression in total CD8+ T cells of patients from the first 
cohort who did not flare was also not confirmed in patients from 
the second cohort. The reasons underlying these discrepancies are 
not fully understood, but may be related to the different treatment 
regimes of the 2 cohorts. Patients from cohort 2 were treated with 
NUC analogues (e.g., LDT, TDF, and ETV) with higher antiviral 
potency than those used for the treatment of patients from cohort 
1 (LAM). Since PD-1 expression on T cells, both at the protein and 
mRNA levels, is suppressed by NUC treatment in proportion to the 
level of HBV reduction (27), treatment with TDF and ETV may ful-
ly suppress T cell expression of PD-1 and thus completely mask the 
cies (>40 SPC/105 cells) that is associated with HBV control in 
the absence of severe hepatic flare upon therapy discontinuation 
(Figure 6G, dotted line). Collectively, our results across 2 distinct 
patient cohorts suggest that if patients display a HBV core and/
or polymerase-specific T cell response above 40 SPC/105 cells, 
they have a high likelihood of controlling HBV without developing 
severe hepatic flares.
In conclusion, our study demonstrates, in 2 independent 
cohorts of chronic HBV patients undergoing long-term NUC ther-
apy, that increased frequencies of functional PD-1+ HBV poly-
merase/core-specific T cells correlate with the absence of hepatic 
flares upon NUC therapy withdrawal.
Discussion
Advanced antiviral agents for the treatment of chronic HBV 
infection are in the development pipeline. However, the imple-
mentation of these new treatments is often complicated by the 
current guidelines, which have recommended maintaining NUC 
therapy indefinitely. Discontinuation of NUCs, the current treat-
ment of choice for chronic HBV patients, is associated with high 
rates of virological relapse and severe hepatic inflammation (23). 
Previous studies have suggested that NUC therapy can be safe-
ly removed only in the very few patients who have experienced 
HBsAg seroconversion or displayed values of HBsAg levels 
below 100 IU/ml (7). Thus, the identification of biological mark-
ers that predict whether NUC therapy can be safely interrupted 
is urgently needed to move forward in the clinical management 
of chronic HBV patients.
To achieve this goal, we characterized antigen-specific and 
global immunological parameters in 2 independent cohorts of 
chronic HBV patients undergoing different regimes of NUC 
therapy. We show that patients who control HBV after therapy 
withdrawal without triggering severe hepatic inflammation are 
characterized, during the course of NUC therapy, by increased 
frequencies of HBV core and polymerase-specific T cells. This rep-
resents, to our knowledge, the first study to report a correlation of 
the quantity and function of HBV-specific T cells with the ability to 
control HBV replication after NUC therapy withdrawal. Our data 
are consistent with previous reports showing that the magnitude 
of the HBV-specific T cell response correlates with HBV control in 
adult chronic HBV patients (15).
In particular, our data demonstrate that HBV-specific T cells 
present in the blood of chronic HBV patients who do not flare are 
selectively enriched within the PD-1+ T cell population and that 
these cells are functional, at least in terms of their proliferative 
capacity and ability to produce IFN-γ. Since PD-1 expression is 
considered the classical hallmark of exhausted T cells (24), our 
results may appear counterintuitive. However, studies performed 
in lymphocytic choriomeningitis virus–infected (LCMV-infect-
ed) mice demonstrate that PD-1 expression on T cells allows the 
improved survival of T cell memory populations that would other-
wise be deleted by the high antigenic load present during chronic 
viral infection (21). Similarly, recent studies show that patients 
with partial immune control of HBV infection display higher lev-
els of intrahepatic PD-1+CD39+ tissue-resident CD8+ T cells that 
possess the capacity to mount immediate and strong cytokine 
responses (25). PD-1 expression on HBV-specific T cells might 
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Patient cohort 2. Twenty-seven HBeAg-negative chronic HBV 
patients on long-term antiviral therapy were enrolled for this study. 
Antiviral therapy consisting of ETV, TDF, or LDT was withdrawn, and 
patients were monitored routinely. Following therapy withdrawal, 
patients differentiated into 2 groups based on the presence or absence 
of hepatic flares during the 8 months (35 weeks) that immediately fol-
lowed treatment withdrawal as described in the main text. Enrollment 
criteria and patient details are shown in Figure 1 and Table 2.
HBV peptide library. Peptide libraries of 313 fifteen-mer peptides 
overlapping by 10 amino acids were used to identify HBV-specific T 
cells. The peptides covered the entire sequence of HBV genotypes B, 
C, and D (GenBank AF121243, AF 112063, AF 21241, respectively) 
and were purchased from Mimotopes. The purity of the peptides was 
above 80%, and their composition was confirmed by mass spectrom-
etry analysis. Peptides were pooled as described previously (13). The 
peptide libraries were matched to the closest HBV genotype of each 
patient, as indicated in Tables 1 and 2.
PBMC isolation and T cell culture. PBMCs were isolated from periph-
eral blood by Ficoll gradient and cryopreserved. Cells were thawed on 
the day of the experiment and were used directly for the ex vivo experi-
ments (NanoString and CyTOF). For the in vitro assays, T cell lines were 
generated as follows: 20% of PBMCs were pulsed with 10 μg/ml of the 
overlapping HBV peptides for 1 hour at 37°C, subsequently washed, and 
cocultured with the remaining cells in AIM-V medium (Gibco; Ther-
mo Fisher Scientific) supplemented with 2% AB human serum (Gibco; 
Thermo Fisher Scientific). T cell lines were cultured for 10 days in the 
presence of 20 U/ml of recombinant IL-2 (R&D Systems).
ELISPOT. ELISPOT assays for the detection of IFN-γ–producing 
cells were performed on in vitro–expanded T cell lines using HBV pep-
tides pooled into the following mixtures: X, core, envelope 1 (env 1), 
env 2, polymerase 1 (pol 1), pol 2, pol 3, pol 4. T cell lines were incubat-
ed overnight at 37°C with pools of HBV peptides (5 μg/ml), where final 
DMSO concentrations did not exceed 0.5%. IFN-γ ELISPOT assays 
(Millipore) were performed as described previously (28).
Intracellular staining. Expanded T cell lines were stimulated over-
night at 37°C with or without HBV peptide pools (5 μg/ml) in the pres-
ence of 2 μg/ml brefeldin A (Sigma-Aldrich). As a positive control, cells 
were stimulated with PMA (2 ng/ml) and ionomycin (1 μg/ml). Cells 
were stained with the yellow LIVE/DEAD fixable dead cell stain kit 
(Invitrogen) and anti-CD3 V500 (clone UCHT1), anti-CD4 BV605 
(clone SK3), and anti-CD8 APC CY7 (clone SK1) antibodies. Cells were 
subsequently fixed and permeabilized using the Cytofix/Cytoperm 
kit (BD Biosciences — Pharmingen) and stained with anti–IFN-γ PE 
(clone 25723, R&D Systems), anti–TNF-α AF 700 (clone MAb11), and 
anti–IL-2 PerCPCY5.5 (clone MQ1-17H12) antibodies and analyzed 
on a BD-LSR II FACS Scan. Data were analyzed by FlowJo (Tree Star 
Inc.). Antibodies were purchased from BD Biosciences — Pharmingen 
unless otherwise stated.
Cell sorting. PBMCs were thawed and used directly for cell sort-
ing on a BD FACSAria, as follows. For the NanoString experiments, 
PBMCs were stained with the Near-IR LIVE/DEAD fixable dead cell 
stain kit (Invitrogen), anti–CD3 V500 (clone UCHT1), anti–CD4-PE 
(clone SK3), and anti–CD8-PECY7 (clone RPA-T8) antibodies. CD4+ 
and CD8+ T cells were purified based on expression of CD3, CD4, and 
CD8 to a purity of greater than 95%. For the PD-1 experiments, cells 
were stained with the Near-IR LIVE/DEAD fixable dead cell stain kit 
(Invitrogen) and anti-CD3 FITC (clone APA 1/1) and anti-CD279 (PD-
differences detected in cohort 1. These considerations are in line 
with the low levels of PD1 mRNA expression detected in CD8+ T 
cells from patients of cohort 2. Of note, the work of McKinney et 
al. (12) shows that T cell exhaustion signatures predictive of disease 
outcomes were evident only during the active phases of diseases. 
Similarly, it is possible that the expression of inhibitory markers 
such as PD1 or TIM3 should be analyzed during the inflammatory/
active phase of disease, when T cells are undergoing activation, 
rather than during NUC therapy, when viral replication is inhibited. 
Unfortunately, the limited availability of PBMC samples from the 2 
patient cohorts did not allow a longitudinal analysis of PD1 expres-
sion at sequential time points of the study.
In summary, the in-depth analysis using traditional and 
recently developed immunological assays identifies in 2 indepen-
dent cohorts the presence of partially exhausted HBV core and 
polymerase-specific T cells as valuable biomarkers of HBV control 
after NUC therapy withdrawal. The implementation of a method-
ology that allows the detection of HBV-specific T cells directly ex 
vivo, without the prior need to expand the cells in vitro, might rep-
resent the necessary step to translate our findings into the clinic 
by developing a reliable, easy to perform, and rapid assay to safely 
identify patients for NUC withdrawal. The sensitivity of such an 
assay may be superior if performed on freshly isolated peripheral 
blood, as recent data suggests that the freezing/thawing process 
introduces functional modifications in T cells that negatively 
affect their functionality as assessed by IFN-γ ELISPOT (Carlo 
Ferrari, personal communication). If successful, an ex vivo T cell 
assay could be easily translated into a clinical diagnostic test. For 
example, QuantiFERON-CMV is a whole blood assay based on the 
measurement of IFN-γ production by T cells following recognition 
of human cytomegalovirus (HCMV) peptides. This kit is routinely 
used in the clinic to monitor T cell–mediated immunity to HCMV, 
which is critical for controlling reactivation of HCMV in the con-
text of organ transplantation.
In conclusion, our study highlights the beneficial role of the 
expression of exhaustion markers on T cells during chronic viral 
infection, since PD-1 expression associates with the long-term per-
sistence of virus-specific T cells in human chronic viral infection. 
Furthermore, our data propose that the levels of residual HBV-spe-
cific T cells present in patients during NUC therapy can be used to 
predict the safe discontinuation of NUC antiviral therapy.
Methods
Patient cohort 1. Twenty-nine HBeAg-negative chronic HBV patients 
on long-term dual antiviral therapy including TDF and LAM were 
enrolled for this study. Patients were treated with dual NUC therapy 
for a minimum of 24 months (median treatment times 36 months; 
range 24–72 months), with patients virally suppressed for at least 18 
months. TDF was then stopped and patients were maintained on LAM 
therapy only for an additional 12 months, after which all NUC thera-
py was discontinued in 21 patients. Patients were monitored routinely 
at 4-week intervals during and for up to 2 years after stopping ther-
apy. Following NUC discontinuation, patients differentiated into 2 
groups based on the absence or presence of hepatic flares during the 6 
months (24 weeks) that immediately followed treatment withdrawal, 
as described in the main text. Enrollment criteria and patient details 
are shown in Figure 1 and Table 1.
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ized using a uniform distribution of values between –1 and 0 in an R 
script. Cells were manually debarcoded using FlowJo. Live lympho-
cytes from different donors were randomly downsampled to 50,000 
events for subsequent high-dimensional data analysis to normalize 
the contribution between donors. Samples were then used for t-SNE 
analysis similar to that previously described (19, 29) using custom R 
scripts based on the “flowCore” and “Rtsne” (using CRAN R pack-
ages that perform the Barnes-Hut implementation of t-SNE) (31). In 
R, all data were transformed using the “logicleTransform” function 
(flowCore package) with the parameters w = 0.25, t = 16409, m = 4.5, 
and a = 0 to roughly match scaling historically used in FlowJo. The 
pie charts (showing average relative frequencies) were generated 
using GraphPad Prism. Heat plots were generated using a custom R 
script after determining the frequency of positive expression using 
gating in FlowJo. For comparison of mean expression of markers on 
total CD4+ and CD8+ T cells, to control for variation in antibody and 
instrument sensitivity between experiments (5–9 patients plus 1 or 
2 healthy donors tested per experiment), we calculated z-scores for 
each phenotypic marker for each batch by subtracting the average 
and dividing by the SD.
Statistics. Statistical significance was determined by GraphPad 
Prism using the nonparametric, 2-tailed Mann-Whitney U test or as 
otherwise stated in the figure legend. Differences were considered 
significant at P ≤ 0.05.
Study approval. All clinical investigations were conducted accord-
ing to Declaration of Helsinki principles. For cohort 1, clinical assess-
ment and peripheral blood sampling were performed during hepati-
tis treatment at the Royal London Hospital (London, UK). Written, 
informed consent was obtained prior to treatment discontinuation, 
and the study was approved by the Barts and the London NHS Trust 
local ethics review board and the NRES Committee London–Research 
Ethics Committee (reference 10/H0715/39). For cohort 2, clinical 
assessment and peripheral blood sampling were performed during 
hepatitis treatment at the National Taiwan University Hospital (n = 20) 
or the National University Hospital of Singapore (Singapore) (n = 7). 
Written, informed consent was obtained prior to treatment discontin-
uation, and the study was approved by the Institutional Review Board 
of National Taiwan University Hospital (201209022RIC) and by the 
Singapore Ethics Committee (2008/005700).
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1) BV 421 (clone EH12.2H7) antibodies. Live CD3+PD-1+, CD3+PD-1–, 
and CD3– populations were purified by cell sorting according to CD3 
and PD-1 expression to a purity of greater than 95 %. Sorted CD3– cells 
were pulsed with HBV polymerase peptides from the corresponding 
HBV genotype for 1 hour at 37°C, washed, and mixed 1:1 with unpulsed 
CD3– cells. CD3– cells were cocultured for 10 days with autologous 
PD-1+ and PD-1– T cells at a 1:1 ratio in the presence of IL-2 (20 U/ml). 
The presence of HBV-specific T cells in PD-1+ and PD-1– fractions was 
assessed by IFN-γ ELISPOT. Antibodies were purchased from BD Bio-
sciences — Pharmingen unless otherwise stated.
NanoString gene expression analysis. CD4+ and CD8+ T cell sub-
sets purified by cell sorting were lysed in RLT lysis buffer (QIAGEN, 
supplemented with 2-mercaptoethanol at 1:100) at a ratio of 1 μl 
RTL:10,000 cells. Cell lysates from a minimum of 20,000 cells were 
analyzed using the preassembled nCounter GX Human Immunology 
Kit and the nCounter system (NanoString Technologies) according 
to the manufacturer’s instructions. Samples were then normalized 
based on the geometric means of both the supplied positive controls 
and the panel of housekeeping genes, as recommended by the manu-
facturer. Only genes that were significantly different (P < 0.05, t test, 
false discover rate [FDR] adjusted) and at least 1.5-fold differentially 
expressed between the 2 groups of patients were considered. For heat-
map representation, the expression level of each gene was log2, which 
was then z-score transformed using a custom R script.
CyTOF. PBMCs were thawed, washed with prewarmed com-
plete RPMI, and rested overnight at 37°C. The following day, cells 
were washed and stained at 37°C in 96-well tissue culture–treated 
round-bottom plates (BD Falcon) with the anti-CD107a antibodies 
(Supplemental Table 1) for 30 minutes prior to stimulation. Cells were 
then stimulated for 4 hours with PMA (150 ng/ml) and ionomycin (1 
μM) in the presence of brefeldin A and monensin (eBioscience). After 
stimulation, cells were washed twice in cold CyFACS buffer (PBS 4% 
FBS, 2 mM EDTA, 0.05% sodium azide) and incubated for 5 minutes 
on ice with Cisplatin (Pt-195, 200 μM, MilliporeSigma) for the mea-
surement of cell viability. Cells were washed and stained with the sur-
face antibody cocktail (Supplemental Table 1) on ice for 30 minutes. 
Cells were washed twice with CyFACS, once with PBS, and then fixed 
in PBS with 2% paraformaldehyde (Electron Microscopy Sciences) at 
4°C. The next day, cells were washed with CyFACS, then incubated 
for 10 minutes with permeabilization buffer (BioLegend) and stained 
with an intracellular antibody cocktail in permeabilization buffer 
(Supplemental Table 1). After 45 minutes at room temperature, cells 
were washed once with permeabilization buffer and once with PBS 
and then incubated with dual mass-tag cellular barcodes, as previ-
ously described (29). After 30 minutes on ice, cells were washed once 
with permeabilization buffer and twice with CyFACS. Cellular DNA 
was labeled at room temperature with iridium interchelator (250 nM, 
Fluidigm) diluted in PBS with 2% paraformaldehyde for 20 minutes. 
Subsequently, cells were washed twice with CyFACS and twice in Mil-
liQ water. Mass cytometry acquisition was performed on a CyTOF2 
instrument. All purified antibodies that lacked carrier proteins were 
purchased from the companies listed in Supplemental Table 1. Anti-
body conjugation was performed according to the protocol provided 
by Fluidigm (see Supplemental Figure 2 for each staining).
CyTOF data analysis. After mass cytometry acquisition, the sig-
nal of each parameter was normalized based on the EQ beads (Flui-
digm) as previously described (30). The 0 values were then random-
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